Immune Response in Decompensated Chronic Heart Failure of Ischemic Origin
Key result
This review discusses the role of monocytes, cytokines, and inflammation in the pathology of chronic heart failure and analyzes drugs used for immune response modulation.
Population
Patients with decompensated chronic heart failure of ischemic origin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Inflammation modulation in ischemic HF remains investigational; leaves open which agents merit randomized testing.
Key Points
- To review the contribution of monocyte activation, cytokine signaling, and disrupted inflammation to the pathogenesis and decompensation of ischemic chronic heart failure, while examining immunomodulatory therapeutic strategies.
- Narrative synthesis of pathophysiological mechanisms linking monocyte activity and pro-inflammatory cytokine production to myocardial injury.
- Literature review of pharmacological agents evaluated for modulating immune responses in chronic heart failure.
- Elevated concentrations of circulating pro-inflammatory cytokines consistently track with increased clinical severity and adverse prognosis in ischemic heart failure.
- Dysregulated transition from physiological myocardial healing to persistent monocyte-mediated inflammation drives pathological remodeling and clinical decompensation.
Structured PICO
P
Population
Patients with decompensated chronic heart failure of ischemic origin
E
Exposure
Drugs used for modulation of immune response
This review highlights the role of inflammation, monocytes, and cytokines in the pathology and decompensation of ischemic chronic heart failure, along with potential immunomodulatory therapies.
Cite This Study
Kruchinkina et al. (2018) conducted a review in Decompensated chronic heart failure of ischemic origin. Immune response modulation drugs was evaluated. This review discusses the role of monocytes, cytokines, and inflammation in the pathology of chronic heart failure and analyzes drugs used for immune response modulation.